FDA Extends Comment Deadline on Drug Scale-Up Rules
Published Date: 6/11/2026
Notice
Summary
The FDA is giving companies more time to share their thoughts on new rules about making and changing medicines after approval. This affects drug makers who want to scale up production or tweak their products. Comments are open until July 13, 2026, so businesses should act fast to help shape these important guidelines that could impact costs and timelines.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-19181, Electronic Submission Template for Medical Device Premarket Approval Applications (PMAs); Draft Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA just dropped a draft guide to help medical device makers submit their big approval applications electronically. This new template aims to make submissions easier, faster, and more consistent for companies working with the FDA’s device and biologics centers. If you’re in the medical device game, check it out and send your feedback by November 17, 2026—no fees or changes yet, just a heads-up for smoother future filings!
2026-19141, Target Animal Safety Evaluation for Veterinary Monoclonal Antibody Products; Draft Guidance for Industry; Availability
The FDA just released a draft guide to help vets and companies test the safety of special animal medicines called veterinary monoclonal antibodies. This new guide aims to make safety testing easier and more consistent worldwide, helping get these medicines to animals faster and safer. If you’re involved in making or testing these products, send your feedback by November 17, 2026, to shape the final rules!
2026-19166, Biosimilar User Fee Act III Future Needs in the Development of Interchangeable Products Post-Workshop; Draft Strategy Document
The FDA just shared a draft plan to help make interchangeable biosimilar drugs easier to develop and approve. This affects drug makers and patients who want more affordable medicine options. The FDA wants your feedback by November 17, 2026, before finalizing the plan, which supports innovation and smoother drug approvals through 2027.
Previous / Next Documents
Previous: 2026-11689, Certain Paper Shopping Bags From Portugal: Rescission of Antidumping Duty Administrative Review; 2024-2025
The U.S. Department of Commerce has canceled the review of special taxes on paper shopping bags from Portugal for January 2024 through June 2025. This means no new fees or changes will happen for these bags during that time. Companies like Finieco and Novolex, who asked for the review, decided to drop it, so everything stays as it was.
Next: 2026-11691, Drug Repurposing for Unmet Medical Needs; Request for Information; Extension of Comment Period
The FDA is giving everyone more time to share their ideas about using existing drugs to help people with medical needs that aren’t being met. This extension means anyone interested—like patients, doctors, or drug makers—can send in their thoughts until July 13, 2026. It’s a smart move to make sure the FDA hears all voices before moving forward with drug repurposing efforts that could save lives and maybe even save money.